Choline-releasing glycerophosphodiesterase EDI3 links the tumor metabolome to signaling network activities

Cell Cycle

Volumn 11, Issue 24, 2012, Pages 4499-4506

  Marchan, Rosemarie ^a   Lesjak, Michaela S ^a   Stewart, Joanna D ^b   Winter, Roland ^c   Seeliger, Janine ^c   Hengstler, Jan G ^a  

^a LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c TU DORTMUND UNIVERSITY   (Germany)

Author keywords

Choline metabolism; Glycerophosphodiesterase; Lysophosphatidic acid; Phosphatidic acid; Signaling networks

Indexed keywords

EDI3 PROTEIN; PHOSPHODIESTERASE; PHOSPHORYLCHOLINE; PROTEIN KINASE C; UNCLASSIFIED DRUG;

CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL MIGRATION; HUMAN; INTRACELLULAR SIGNALING; KENNEDY PATHWAY; MALIGNANT NEOPLASTIC DISEASE; METABOLITE; METABOLOME; NONHUMAN; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; TUMOR METABOLOME;

EID: 84871482516     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22544     Document Type: Review

References (45)

1. Stewart JD, Marchan R, Lesjak MS, Lambert J, Hergenroeder R, Ellis JK, et al. Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis. Proc Natl Acad Sci USA 2012; 109:8155-60; PMID:22570503; http://dx.doi.org/10.1073/pnas.1117654109.
2. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010; 50:157-86; PMID:20055701; http://dx.doi.org/10.1146/annurev.pharmtox.010909. 105753.
3. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3:582-91; PMID:12894246; http://dx.doi.org/10.1038/ nrc1143.
4. Stapleton CM, Mashek DG, Wang S, Nagle CA, Cline GW, Thuillier P, et al. Lysophosphatidic acid activates peroxisome proliferator activated receptor-γ in CHO cells that over-express glycerol 3-phosphate acyltransferase-1. PLoS One 2011; 6:e18932; PMID:21533082; http://dx.doi.org/10. 1371/journal.pone.0018932.
5. Robbins GT, Nie D. PPAR gamma, bioactive lipids, and cancer progression. Front Biosci 2012; 17:1816-34; PMID:22201838; http://dx.doi.org/10.2741/4021.
6. Steinberg SF. Structural basis of protein kinase C isoform function. Physiol Rev 2008; 88:1341-78; PMID:18923184; http://dx.doi.org/10.1152/physrev. 00034.2007.
7. Dries DR, Gallegos LL, Newton AC. A single residue in the C1 domain sensitizes novel protein kinase C isoforms to cellular diacylglycerol production. J Biol Chem 2007; 282:826-30; PMID:17071619; http://dx.doi.org/10. 1074/jbc.C600268200.
8. Foster DA. Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochim Biophys Acta 2009; 1791:949-55; PMID:19264150; http://dx.doi.org/10.1016/j.bbalip.2009.02.009.
9. Gomez-Cambronero J. New concepts in phospholipase D signaling in inflammation and cancer. ScientificWorldJournal 2010; 10:1356-69; PMID:20623096; http://dx.doi.org/10.1100/tsw.2010.116.
10. Kang DW, Choi KY, Min S. Phospholipase D meets Wnt signaling: a new target for cancer therapy. Cancer Res 2011; 71:293-7; PMID:21224347; http://dx.doi.org/10.1158/0008-5472.CAN-10-2463.
11. Noh DY, Ahn SJ, Lee RA, Park IA, Kim JH, Suh PG, et al. Overexpression of phospholipase D1 in human breast cancer tissues. Cancer Lett 2000; 161:207-14; PMID:11090971; http://dx.doi.org/10.1016/S0304-3835(00)00612-1.
12. Su W, Chen Q, Frohman MA. Targeting phospholipase D with small-molecule inhibitors as a potential therapeutic approach for cancer metastasis. Future Oncol 2009; 5:1477-86; PMID:19903073; http://dx.doi.org/10.2217/fon.09.110.
13. Chae YC, Kim JH, Kim KL, Kim HW, Lee HY, Heo WD, et al. Phospholipase D activity regulates integrin-mediated cell spreading and migration by inducing GTP-Rac translocation to the plasma membrane. Mol Biol Cell 2008; 19:3111-23; PMID:18480413; http://dx.doi.org/10.1091/mbc.E07-04-0337.
14. Consonni SV, Gloerich M, Spanjaard E, Bos JL. cAMP regulates DEP domain-mediated binding of the guanine nucleotide exchange factor Epac1 to phosphatidic acid at the plasma membrane. Proc Natl Acad Sci USA 2012; 109:3814-9; PMID:22343288; http://dx.doi.org/10.1073/pnas.1117599109.
15. Zhao C, Du G, Skowronek K, Frohman MA, Bar-Sagi D. Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos. Nat Cell Biol 2007; 9:706-12; PMID:17486115; http://dx.doi.org/10.1038/ ncb1594.
16. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001; 294:1942-5; PMID:11729323; http://dx.doi.org/10.1126/science.1066015.
17. Ghosh S, Strum JC, Sciorra VA, Daniel L, Bell RM. Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid regulates the translocation of Raf-1 in 12-O- tetradecanoylphorbol-13-acetate-stimulated Madin-Darby canine kidney cells. J Biol Chem 1996;271:8472-80; PMID:8626548.
18. Rizzo MA, Shome K, Vasudevan C, Stolz DB, Sung TC, Frohman MA, et al. Phospholipase D and its product, phosphatidic acid, mediate agonist-dependent raf-1 translocation to the plasma membrane and the activation of the mitogen-activated protein kinase pathway. J Biol Chem 1999; 274:1131-9; PMID:9873061; http://dx.doi.org/10.1074/jbc.274.2.1131.
19. Weise K, Kapoor S, Denter C, Nikolaus J, Opitz N, Koch S, et al. Membrane-mediated induction and sorting of K-Ras microdomain signaling platforms. J Am Chem Soc 2011; 133:880-7; PMID:21141956; http://dx.doi.org/10. 1021/ja107532q.
20. Kapoor S, Triola G, Vetter IR, Erlkamp M, Waldmann H, Winter R. Revealing conformational substates of lipidated N-Ras protein by pressure modulation. Proc Natl Acad Sci USA 2012; 109:460-5; PMID:22203965; http://dx.doi.org/10. 1073/pnas.1110553109.
21. Weise K, Triola G, Brunsveld L, Waldmann H, Winter R. Influence of the lipidation motif on the partitioning and association of N-Ras in model membrane subdomains. J Am Chem Soc 2009; 131:1557-64; PMID:19133719; http://dx.doi.org/ 10.1021/ja808691r.
22. Marchan R, Stewart JD, Lesjak MS, Keun HC, Schmitz G, Hengstler JG. Untangling the contribution of choline metabolism to the metastatic process. Proc Natl Acad Sci USA 2012; 109; http://dx.doi.org/10.1073/pnas.1209917109.
23. Newton AC. Protein kinase C: poised to signal. Am J Physiol Endocrinol Metab 2010; 298:E395-402; PMID:19934406; http://dx.doi.org/10.1152/ajpendo. 00477.2009.
24. Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer 2010; 102:941-6; PMID:20234370; http://dx.doi.org/10.1038/sj.bjc.6605588.
25. Moestue SA, Giskeødegård GF, Cao MD, Bathen TF, Gribbestad IS. Glycerophosphocholine (GPC) is a poorly understood biomarker in breast cancer. Proc Natl Acad Sci USA 2012; 109:E2506; PMID:22851771; http://dx.doi.org/10.1073/pnas.1208226109.
26. Gallego-Ortega D, Gómez del Pulgar T, Valdés-Mora F, Cebrián A, Lacal JC. Involvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functions. Adv Enzyme Regul 2011; 51:183-94; PMID:21035492; http://dx.doi.org/ 10.1016/j.advenzreg.2010.09.010.
27. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 2005; 65:9369-76; PMID:16230400; http://dx.doi.org/10.1158/0008- 5472.CAN-05-1146.
28. Bell JD, Cox IJ, Sargentoni J, Peden CJ, Menon DK, Foster CS, et al. A 31P and 1H-NMR investigation in vitro of normal and abnormal human liver. Biochim Biophys Acta 1993; 1225:71-7; PMID:8241291; http://dx.doi.org/10.1016/ 0925-4439(93)90124-J.
29. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999; 59:80-4; PMID:9892190.
30. Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer 2007; 120:1721-30; PMID:17236204; http://dx.doi.org/10.1002/ijc.22293.
31. Sabatier J, Gilard V, Malet-Martino M, Ranjeva JP, Terral C, Breil S, et al. Characterization of choline compounds with in vitro 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors. Invest Radiol 1999; 34:230-5; PMID:10084669; http://dx.doi.org/10.1097/00004424-199903000-00013.
32. Cox IJ, Bell JD, Peden CJ, Iles RA, Foster CS, Watanapa P, et al. In vivo and in vitro 31P magnetic resonance spectroscopy of focal hepatic malignancies. NMR Biomed 1992; 5:114-20; PMID:1322688; http://dx.doi.org/10.1002/nbm. 1940050303.
33. Cao MD, Giskeødegård GF, Bathen TF, Sitter B, Bofin A, Lønning PE, et al. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer 2012; 12:39; PMID:22277092; http://dx.doi.org/10.1186/1471-2407-12-39.
34. Giskeødegård GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjøsne HE, et al. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res 2010; 9:972-9; PMID:19994911; http://dx.doi.org/10.1021/pr9008783.
35. Cao MD, Döpkens M, Krishnamachary B, Vesuna F, Gadiya MM, Lønning PE, et al. Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR Biomed 2012; 25:1033-42; PMID:22279038; http://dx.doi.org/10.1002/nbm.2766.
36. Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Børresen-Dale AL, et al. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer 2010; 10:433; PMID:20716336; http://dx.doi.org/10.1186/1471-2407-10-433.
37. Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Humpfer E, Spraul M, et al. Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res 2010; 9:319-32; PMID:19908917; http://dx.doi.org/10.1021/pr9006574.
38. Gribbestad IS, Sitter B, Lundgren S, Krane J, Axelson D. Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. Anticancer Res 1999; 19(3A):1737-46; PMID:10470108.
39. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001; 61:3599-603; PMID:11325827.
40. Franks SE, Smith MR, Arias-Mendoza F, Shaller C, Padavic-Shaller K, Kappler F, et al. Phosphomonoester concentrations differ between chronic lymphocytic leukemia cells and normal human lymphocytes. Leuk Res 2002; 26:919-26; PMID:12163053; http://dx.doi.org/10.1016/S0145-2126(02)00035-8.
41. Keshari KR, Tsachres H, Iman R, Delos Santos L, Tabatabai ZL, Shinohara K, et al. Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment. NMR Biomed 2011; 24:691-9; PMID:21793074; http://dx.doi.org/10. 1002/nbm.1738.
42. McKnight TR, Smith KJ, Chu PW, Chiu KS, Cloyd CP, Chang SM, et al. Choline metabolism, proliferation, and angiogenesis in nonenhancing grades 2 and 3 astrocytoma. J Magn Reson Imaging 2011; 33:808-16; PMID:21448944; http://dx.doi.org/10.1002/jmri.22517.
43. Righi V, Roda JM, Paz J, Mucci A, Tugnoli V, Rodriguez-Tarduchy G, et al. 1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas. NMR Biomed 2009; 22:629-37; PMID:19322812; http://dx.doi.org/10.1002/nbm.1377.
44. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, et al. Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med 2008; 60:33-40; PMID:18581409; http://dx.doi.org/10.1002/mrm.21647.
45. Albers MJ, Krieger MD, Gonzalez-Gomez I, Gilles FH, McComb JG, Nelson MD Jr., et al. Proton-decoupled 31P MRS in untreated pediatric brain tumors. Magn Reson Med 2005; 53:22-9; PMID:15690498; http://dx.doi.org/10.1002/mrm.20312.